Supplementary Figure 3 from The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models
Year: 2025
Type: supplementary-materials
Abstract: Treatment of an NSCLC model with azenosertib + adagrasib results in biomarker changes in vitro and in vivo.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4410345370